FDA Broadens Eligibility Criteria for Oncology Clinical Trials to Increase Patient Access

The U.S. Food and Drug Administration (FDA) has finalized three guidance documents aimed at making clinical trials for oncology drugs more accessible. These documents encourage sponsors to reconsider restrictive eligibility criteria related to performance status, washout periods, concomitant medications, and laboratory values. Experts believe these updates will broaden trial participation, particularly for patients with more complex medical histories who have historically been underrepresented in clinical research.